HCA Healthcare price target lowered to $300 from $340 at Truist

Truist lowered the firm’s price target on HCA Healthcare to $300 from $340 and keeps a Buy rating on the shares. The company’s Q3 results were mixed, which was tied largely to margin pressures from the Valesco JV and professional fees, though the firm remains bullish on the stock and continues to view HCA’s underlying trends favorably, the analyst tells investors in a research note. The company’s core labor trends remain strong, volumes were largely solid, and HCA’s scale, positioning and ongoing investment should underpin strong ongoing core trends, the firm added.